Clinicians get new protocol for anti-obesity drug

The Korea Food and Drug Administration (KFDA) unveiled a new set of protocols for anti-obesity drug based on some guidelines of the U.S. Food and Drug Administration and Europe's EMEA, which will be of much help to drug makers and clinicians.

The anti-obesity protocol includes indications, selection/exclusion criteria of subjects, end-point parameters, analytical method, and clinical conside...